Introduction:
The presence of frontal and/or temporal atrophy on neuroimaging has been designated as supportive in the clinical consensus criteria for behavioral variant frontotemporal dementia (bvFTD). As magnetic resonance imaging (MRI) has a relatively low sensitivity for bvFTD, a substantial proportion of patients may present with a normal MRI. Thus, there may be clinical differences between patients with and without lobar abnormalities on MRI. We compared clinical characteristics of bvFTD patients with frontotemporal lobar atrophy on MRI to those lacking the typical pattern at presentation.
Methods: MRIs of 49 patients from our memory clinic, diagnosed with bvFTD were rated for the presence or absence of frontal and/or temporal atrophy. Demographic, behavioral, and cognitive features were compared between subjects with and without typical bvFTD atrophy pattern.
Results: Twenty-three patients showed lobar atrophy on MRI, whereas 26 patients lacked the characteristic frontotemporal lobar atrophy, including 13 patients with a normal MRI and 13 with other abnormalities. Disinhibition occurred more often in the group with frontal and/or temporal atrophy on MRI compared with the group with other abnormalities, whereas imitation did not occur in patients lacking the typical bvFTD atrophy pattern. No differences were found in neuropsychologic profiles. There was a trend for a lower mean Clinical Dementia Rating and less severe language impairment in patients with a normal MRI compared with the group with frontal and/or temporal atrophy.
Conclusions:
The clinical phenotype of FTD cannot be predicted by the presence or absence of lobar atrophy on MRI, although imitation and disinhibition are more prevalent in bvFTD patients with characteristic MRI abnormalities. Furthermore, patients with a normal MRI seem to be less severely demented in comparison to patients with frontal and/or temporal atrophy. A ccording to the clinical consensus criteria, frontotemporal dementia (FTD), the behavioral subtype of frontotemporal lobar degeneration (FTLD), is characterized by a gradual decline in social and personal behavior with loss of empathy and insight. 1 Several other behavioral symptoms, such as loss of initiative, disinhibition, and hyperorality are supportive features for the diagnosis of behavioral variant FTD (bvFTD). bvFTD is associated with atrophy of the frontal and/or temporal lobes. 2, 3 Although lobar atrophy is frequently present in patients with bvFTD, there is a wide variability in the extent of the atrophy and asymmetry is often observed. [4] [5] [6] [7] Moreover, the presence of frontal and/or temporal lobar atrophy on neuroimaging is only a supportive feature and not mandatory for the diagnosis of bvFTD. 1 The sensitivity of structural neuroimaging for bvFTD varies in different studies from 47% to 85%. [8] [9] [10] [11] Thus, a substantial proportion of patients with bvFTD may have a normal magnetic resonance imaging (MRI) at presentation and may develop the specific atrophy pattern on MRI over time. 6, 11, 12 Lobar atrophy on MRI has been described to be absent in a subgroup of bvFTD patients with a relatively benign course. 13 It has been suggested by the same group that patients with a normal MRI have a much slower cognitive decline, but share the same behavioral features. 11, 14 These findings have not yet been confirmed by others. On the one hand, a normal scan might be the reflection of early stage bvFTD, but in contrast, patients with a slowly progressive clinical variant of bvFTD may have a normal scan for years. Therefore, our aim was to compare the demographic, behavioral, and cognitive characteristics between bvFTD patients with frontal and/or temporal lobar atrophy on MRI and patients lacking the typical FTD pattern at the time of diagnosis. We hypothesized that patients with a normal MRI at presentation were less severely demented. Moreover, if subjects with a normal MRI represent a distinct clinical subgroup, they might differ from ''classic bvFTD'' with respect to behavioral and cognitive characteristics.
METHODS

Patients
Forty-nine consecutive patients with bvFTD were included from the Alzheimer centre of the Vrije University medical centre in Amsterdam. For the diagnostic procedure, all patients underwent a standard battery of investigations including a patient and informant-based medical history, physical, and neurologic examination including mini-mental state examination (MMSE), laboratory tests, neuropsychologic assessment, electroencephalography, and MRI of the brain. The diagnosis of bvFTD was made by a multidisciplinary team, including a neurologist, psychiatrist, neurophysiologist, neuropsychologist, and specialized nurses, based on the clinical consensus criteria. 1 Dementia severity was rated using the Clinical Dementia Rating (CDR). 15 All subjects gave informed consent for their clinical data to be used for research.
It is noted that the patients' diagnosis was established clinically and not on basis of their imaging findings, conform the consensus criteria. In line with the clinical criteria, certain imaging findings, such as brain tumors, excluded the diagnosis of bvFTD.
All patients had at least 1 year of clinical follow-up. Additional imaging included 99mTc-hexamethyl propyleneamine oxide single photon emission computed tomography (SPECT) or [18] -F-fluorodeoxyglucose-positron emission tomography (PET), and/or repeated MRIs.
Clinical Evaluation
Demographical, behavioral, and cognitive characteristics at presentation were retrospectively rated from the patient files. All patients had routinely undergone a standardized caregiver-based behavioral interview and standardized behavioral observation, a cognitive assessment, and a psychiatric evaluation. Behavioral features included loss of initiative/apathy, compulsory behavior, disinhibition, perseveration, echolalia, imitation, utilization, and hyperorality, which are all supportive features for the diagnosis of bvFTD. All features were rated as present or not present. As this is a retrospective study, no uniform neuropsychologic test battery was used. Therefore, from the neuropsychologic assessment impairment in memory, language, executive, and visuospatial functions was rated as absent, mild, moderate, or severe, for each patient individually based on the scores of the different tests used. Tests included the Visual Association Test (VAT), the Rey auditory-verbal learning test (episodic memory), digit spans forwards and backwards (working memory), and category fluency (semantic memory). [16] [17] [18] For executive dysfunction the following tests were used: the Trail Making Test B, elements of the Behavior Assessment of Dysexecutive Syndrome, and the Stroop and letter fluency. [19] [20] [21] The Boston naming test and VAT naming were used for naming and the Rey-Osterrieth Complex Figure Copying test for evaluating visuospatial function. 16, 22, 23 Neuroimaging MRIs were acquired on a 1.0 T scanner (Siemens Magnetom Impact Expert, Erlangen, Germany). All subjects were scanned following a standard MRI protocol for dementia including coronal T1-weighted 3-dimensional magnetization prepared rapid acquisition gradient echo (168 slices; field of view = 250 mm; matrix 256 Â 256; slice thickness = 1.5 mm; echo time = 7 ms; repetition time = 15 ms; inversion time = 300 ms; and flip angle = 5 degree), axial fluid-attenuated inversion recovery (FLAIR; 17 slices; field of view = 250 mm; matrix = 256 Â 256; slice thickness = 5 mm; interslice gap = 1.5 mm; echo time = 105 ms; repetition time = 9000 ms; inversion time = 2200 ms; and flip angle = 180 degree), and axial T2-weighted gradient echo sequences (19 slices; field of view = 250 mm; matrix = 256 Â 256; slice thickness = 5 mm; interslice gap = 1.5 mm; echo time = 22 ms; repetition time = 800 ms; and flip angle 20 degree).
MRI scans of the 49 patients with a clinical diagnosis of bvFTD and MRI scans from 10 patients with Alzheimer disease (AD) and 10 patients with subjective memory complaints, who had undergone the same diagnostic procedure, were rated by 2 experts in imaging in dementia (F.B. and P.S.), who were blinded for the clinical diagnosis. The imaging data of the 20 non-FTD subjects served to assure blinded assessment, but were not further used in the analysis.
The patients were divided into separate groups. In the first group, MRI of the brain revealed an atrophy pattern typical for FTD (frontal and/or temporal atrophy), whereas in the second group no specific abnormalities were observed. The latter group consisted of 2 different subgroups, patients with a normal MRI and patients with other abnormalities, which were separately used in statistical analysis. The division in these groups was based on visual judgment, throughout the entire volume, whether or not a MRI showed an atrophy pattern characteristic for FTD. In case of disagreement (14 cases, equally distributed between the groups), consensus was reached. Cohen Kappa for agreement between the 2 raters was 0.57, which denotes a moderate agreement.
For the MRIs in accordance with FTD further specification about the most affected side (left or right) and lobe (temporal, frontal, or both) was given. All MRIs were rated for atrophy of the frontal (orbitofrontal, dorsolateral, and mediofrontal) and parietal lobes, using a 4-point (0 to 3) rating scale. 24 Temporal lobe atrophy was rated according to the Galton scale. 25 Medial temporal lobe atrophy (MTA) was scored using the Scheltens scale, which is a 5-point (0 to 4) visual rating scale. 26 The presence of vascular white matter damage was scored according to the 4-point (0 to 3) rating scale described by Fazekas et al. 27 The assessment of frontal, parietal, and temporal lobe atrophy was based on axial 2-dimensional FLAIR images and MTA analysis was based on coronal T1-weighted images.
Statistical Analysis
For statistical analysis SPSS version 14.0 was used. Groups were compared using w 2 test for categorical data and analysis of variance with post-hoc Least Significant Difference t tests for continuous data. Statistical significance was set at P value less than 0.05.
RESULTS
Twenty-three patients had lobar atrophy on MRI. Of these, there were 13 patients with predominant frontal atrophy, 8 patients with predominant temporal atrophy, and 2 patients with frontotemporal atrophy. Asymmetrical atrophy on left or right side occurred in 4 patients (13%). Twenty-six patients did not have a scan appearance characteristic for bvFTD, including 13 patients with a completely normal MRI and 13 patients with other abnormalities. These consisted of a more global atrophy pattern, varying from mild atrophy (6 patients) to moderate-tosevere atrophy (7 patients). Of the latter group, 2 patients also had vascular lesions, which did not fulfil the criteria for vascular dementia. 28 In Figure 1 , representative MRI images of each group are shown. Additional imaging (PET, SPECT, or MRI) was available for 12 out of the 13 patients with a normal scan at presentation. Five of the patients had frontotemporal changes on PET or SPECT, whereas in 1 patient the third MRI (5 y after the first MRI) showed frontal atrophy. Six patients with a normal MRI at presentation did not develop frontotemporal changes on either MRI, PET, or SPECT (follow-up time varied between 1 and 9 y). In 13 patients with other abnormalities on MRI at presentation, follow-up imaging was available for 8 patients. In 6 of these patients abnormalities suggestive for FTD were observed (2 times on PET/SPECT and 4 times on additional MRI). Demographic characteristics of the 3 patients groups are listed in Table 1 . The groups were comparable with respect to age at onset, sex distribution, MMSE, duration of symptoms, and CDR. However, there was a trend for a lower CDR score in the group with normal MRI (P = 0.06) compared with patients with frontal and/or temporal atrophy.
Atrophy scores are shown in Table 2 . Temporal and frontal lobe atrophy and MTA occurred more often in patients with characteristic MRI abnormalities in comparison to patients with either a normal MRI or with other abnormalities on MRI. Parietal atrophy was a remarkable finding in patients with characteristic MRI abnormalities and in patients with other abnormalities on MRI.
Behavioral features of the patient groups are listed in Table 3 . Loss of initiative/apathy, hyperorality, compulsory behavior, and perseveration were frequently noticed in all groups, whereas echolalia and utilization occurred less often in both groups. Disinhibition was the only behavioral feature that occurred significantly more often in the group with frontal and/or temporal atrophy on MRI compared with patients with other abnormalities (P = 0.01). Although imitation did not occur in either patients with normal MRI or patients with other abnormalities, compared with 17% in the group with frontal and/or temporal atrophy, this difference did not reach statistical significance. Table 4 shows the cognitive characteristics of the 3 groups. Comparison of the results on neuropsychologic examination revealed that language impairment was less severe in the group with a normal MRI compared with both other groups. In all groups, the presence of executive dysfunction was the most prevalent.
DISCUSSION
In this study, we compared demographical, behavioral, and cognitive characteristics of bvFTD patients with a typical atrophy pattern on MRI with patients lacking such patterns.
We found that the patients without a typical atrophy pattern on MRI could be divided into patients with a normal MRI and patients with other abnormalities.
Disinhibition occurred more often in patients with frontal and/or temporal lobar atrophy pattern on MRI compared with patients with other abnormalities. Moreover, imitation did not occur in patients without the typical FTD atrophy pattern and was only present in a small proportion of patients with frontotemporal atrophy. We also found that the patients with a completely normal MRI seem to be less severely demented and had less severe language impairment.
It is well known that the profound alteration of personality in bvFTD is often characterized by social disinhibition. 1, 29 Disinhibition has been found to be one of the most discriminating features between bvFTD and AD. 30 Disinhibition is associated with lesions of the orbitofrontal cortex, which is found to be the first affected region in bvFTD patients. 6 One study found that disinhibition scores on the neuropsychiatric inventory were correlated with orbitofrontal atrophy. 31 Another study looked at the neuroanatomic correlations in a group of 62 bvFTD patients between the 2 main behavioral abnormalities described in bvFTD, apathy, and disinhibition. 32 They found a correlation between disinhibition and atrophy in the right nucleus accumbens, right superior temporal sulcus, and right mediotemporal limbic structures.
Imitation is a known behavioral change in people with frontal lobe damage or dysfunction. 33 It is also a symptom that is frequently noticed in a subtle form in demented and depressed patients. 34 Obstinate imitation, in which a patient keeps on imitating gestures even after an instruction not to do so, occurred only in bvFTD patients as opposed to AD patients. 35 Our findings could suggest that the patient group with frontal and/or temporal atrophy, based on higher prevalence of these specific symptoms (imitation and disinhibition), is more likely to have FTD than the group without specific atrophy patterns. In contrast, however, we found no differences in clinical phenotypes regarding many other hallmarks of bvFTD.
It could be argued that the patient group with other abnormalities on MRI could exist of patients with underlying AD pathology. It is known that AD can present with a more frontal phenotype. 36 Although MTA is considered characteristic for AD, 37 it does occur in FTLD as well. [38] [39] [40] As we found a low degree of MTA in the group with other abnormalities (mean MTA 0.9 ± 0.9), it is unlikely that this group consists of patients with AD. Our findings plead for the presence of atypical MRI abnormalities in a subgroup of patients with bvFTD. Unfortunately, as pathologic confirmation of the diagnosis FTD is missing, misdiagnosis cannot be fully excluded.
When we compared patients with frontal and/or temporal atrophy on MRI with patients with a completely normal MRI, we found that the 2 groups did not differ with respect to demographic and behavioral characteristics. However, in line with our hypothesis, the patients with a normal MRI were less severely demented and had less severe language impairment. There were no other differences in scores at neuropsychologic impairment or MMSE score. Our findings are in line with the findings of one study that patients with normal scan appearances shared the same marked abnormal behavior as patients with atrophy on MRI at presentation, but had less cognitive dysfunction and overall disability. 11 In another study, the same group found that patients with a normal MRI at presentation seem to follow a more benign course. 13 In that report, none of the patients without brain atrophy or only borderline atrophy died or was institutionalized compared with the group with unequivocal brain atrophy after a minimum of 3-years follow-up. We could not fully confirm these findings, as our study lacks the prospective design. As the sensitivity of MRI for bvFTD is relatively low, it might well be possible that a large proportion of our patients have classic bvFTD with the typical imaging pattern evolving over time. Additional neuroimaging in our study suggests that in half of the patients with normal MRIs at baseline ''classic'' bvFTD develops over time and the other half has a possible benign bvFTD variant, although long-term follow-up would be needed to confirm this.
Remarkably, we did not find differences in disease duration between the groups, suggesting that the explanation that bvFTD patients with normal scans are in an earlier stage of the disease does not hold true for the majority of cases.
The question might be raised whether patients with a normal scan appearance might have an alternative underlying substrate causing these changes in behavior, for example, a psychiatric disorder. In our group, however, misdiagnosis of psychiatric disorders in the subjects with normal MRI was unlikely as an extensive evaluation by a psychiatrist did not reveal any psychiatric disorders (eg, depression or personality disorders) in these cases. Moreover, it is known that patients diagnosed with bvFTD with a distinct clinical profile, but with a normal scan during the course of their disease, may have the underlying pathology of FTLD-ubiquitine-only-immunoreactive neuronal inclusions with hippocampal sclerosis. 41 In conclusion, we studied a group of bvFTD patients with well-documented demographical, behavioral, and cognitive features and found that patients with bvFTD have a heterogeneous aspect on MRI at presentation, varying from a normal aspect to diffuse cortical atrophy and frontal and/or temporal atrophy. About one third of the patients had nonspecific MRI-abnormalities, not sufficient to exclude a diagnosis of bvFTD. The fact that imaging just plays a supportive role in the diagnosis of bvFTD seems to be justified, as we found no major differences in behavioral and cognitive presentation of patients with and without frontotemporal lobar atrophy. However, for adding a degree of certainty to the clinical diagnosis neuroimaging could be useful and additional neuroimaging is certainly indicated in case of a normal MRI in suspected bvFTD.
For clinicians, it is important to be aware that the characteristic pattern of frontotemporal atrophy may occur in less than half of the cases presenting with bvFTD. A normal scan or an atypically abnormal scan does not exclude the diagnosis bvFTD. Further research is essential, especially longitudinal MRI studies, which should make clear which proportion of normal MRIs represent early classic bvFTD and to what extent a ''benign'' subtype of bvFTD is present, characterized by a normal MRI and little clinical progression over a longer period of time.
